SEARCH

SEARCH BY CITATION

References

  • 1
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. New Engl J Med 1989; 321: 15011506.
  • 2
    Poynard T, Leroy V, Cohard M, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trial in the treatment of viral hepatitis C. Effects of dose and duration [Abstract]. Hepatology 1995; 22: 113A.
  • 3
    Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 20: 13.
  • 4
    Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pre-treatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 10501056.
  • 5
    Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 13261329.
  • 6
    Davis GL. Interferon treatment of cirrhotic patients with chronic hepatitis C: a logical intervention [Editorial]. Am J Gastroenterol 1994; 89: 658660.
  • 7
    Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C. Ann Intern Med; in press.
  • 8
    Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 14571462.
  • 9
    Métreau JM, the French Group for the study of NANB/C chronic hepatitis treatment. Results of long term interferon treatment in non-A, non-B/C chronic active hepatitis. Gut 1993; 34 (suppl): S112113.
  • 10
    Saracco G, Rosina F, Torrani-Cerenzia MR, Lattore V, Chiandussi L, Gallo V, Petrino R, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990; I (Suppl 1): 4349.
  • 11
    Yuki N, Hayahi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, Katayama K, et al. Pre-treatment viral load and response to prolonged interferon alpha course for chronic hepatitis C. J Hepatol 1995; 22: 457463.
  • 12
    Suzuki T, Tanaka E, Matsumoto A, Urushihara A, Sodeyama T. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy. J Med Virol 1995; 46: 162168.
  • 13
    Orito E, Mizokami M, Suzuki K, Ohba T, Mori M, Hayashi K, Kato K, et al. Loss of serum HCV RNA at week 4 of interferon alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis. J Med Virol 1995; 46: 109115.
  • 14
    Garson JA, Brillanti S, Whitby K, Foli M, Deaville R, Masci C, Miglioli M, et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 1995; 45: 348353.
  • 15
    Orito E, Mizokami M, Nakano T, Terashima H, Nojiri O, Sakakibara K, Mizuno M, et al. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon alpha therapy in Japanese patients with chronic hepatitis C. J Med Virol 1994; 44: 410414.
  • 16
    Yun ZB, Reichard O, Chen M, Lundeberg J, Norkrans G, Fryden A, Sonnerborg A, et al. Serum hepatitis C virus RNA levels in chronic hepatitis C–importance for outcome of interferon alfa-2b treatment. Scand J Infect Dis 1994; 26: 263270.
  • 17
    Mita E, Hayahi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA liter. Dig Dis Sci 1994; 39: 977982.
  • 18
    Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon alpha 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 39: 12731280.
  • 19
    Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 15011504.
  • 20
    Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293299.
  • 21
    Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996; 24: 10341040.
  • 22
    Collins ML, Zayati C, Detmer JJ, Daly B, Kolberg JA, Cha T-A, Irvine BD, et al. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem 1995; 226: 120129.
  • 23
    Pozzato G, Moretti M, Croce LS, Sasso F, Kaneko S, Unoura M, Kobayashi K, et al. Interferon therapy in chronic hepatitis C virus: evidence of different outcome with respect to different viral strains. J Med Virol 1995; 45: 445450
  • 24
    Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. Randomized trial comparing three different regimens of alpha 2a interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology 1995; 22: 700706.
  • 25
    Booth JC, Foster GR, Kumar U, Galassini R, Goldin RD, Brown JL, Thomas HC. Chronic hepatitis C virus infection: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha. Gut 1995; 36: 427432.
  • 26
    Mahaney K, Tedeschi V, Maertens F, DiBisceglie AM, Vergalla J, Hoof-nagle JH, Sallie R. Genotypic analysis of hepatitis C virus in American patients. Hepatology 1994; 20: 14051411.
  • 27
    Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, et al. Factors predictive of response to interferon alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 10881094.
  • 28
    Mizokami M, Lau JYN, Suzuki K, Nakano T, Gojobori T. Differential sensitivity of hepatitis C virus quasispecies to interferon alpha therapy. J Hepatol 1994; 21: 884886.
  • 29
    Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, Sato C. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995; 22: 3035.
  • 30
    Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus Ib. J Clin Invest 1995; 96: 224230.
  • 31
    Herion D, Hoofnagle JH. The interferon sensitivity determining region: All hepatitis C virus isolates are not the same. Hepatology 1997; 25: 769771.
  • 32
    Yamada G, Takahashi M, Endo H, Doi T, Miyamoto R, Shimomura H, Yamamoto K, et al. Quantitative hepatitis C virus RNA and liver histology in chronic hepatitis C patients treated with interferon alfa. Gut 1993; 34 (suppl 2): S133134.
  • 33
    Camps J, Garcia-Granero M, Riezo-Boj JI, Larrea E, de Alava E, Civeira MP, Castilla A, et al. Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol 1994; 21: 411.
  • 34
    Magrin S, Craxi A, Fabiano C, Fiorentino G, Marino L, Almasio P, Pinzello GB, et al. Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis. J Med Virol 1992; 38: 200206.
  • 35
    Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of 3 interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. New Engl J Med 1995; 332: 14571462.
  • 36
    Reichard O, Norkrans G, Fryden A, Braconier JH, Alacus A, Glaumann H, Schvarcz A, et al. Interferon alpha and ribavirin versus interferon alpha alone as therapy for chronic hepatitis C–a randomized double-blind placebo-controlled study [Abstract]. Hepatology 1996; 24: 356A.
  • 37
    Davis GL, Lau JYN, Urdea MS, Neuwald P, Wilber JC, Lindsay K, Perrillo RP, et al. Quantitative detection of hepatitis C virus (HCV) RNA by a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994; 19: 13371341.
  • 38
    Alter HJ, Sanchez-Pescador R, Urdea MS, Wilber JC, Lagier RJ, DiBisceglie AM, Shih JW, et al. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepatitis 1995; 2: 121132.
  • 39
    Nelson DR, Marousis CG, Davis GL, Lau JYN. Defining the role of intrahepatic HCV-specific cytotoxic T-lymphocytes in chronic hepatitis C [Abstract]. Hepatology 1995; 22: 287A.
  • 40
    Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, Combs C, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317322.
  • 41
    Van Thiel DH, Fagiuoli S, Caraceni P, Wright HI, Nadir A, Gavaler JS, Zuhdi N. Cryoglobulinemia: a cause for false negative polymerase chain reaction results in patients with hepatitis C virus positive chronic liver disease. J Hepatol 1995; 22: 464467.
  • 42
    Lau JYN, Simmonds P, Urdea MS. Implications of variations of “conserved” regions of hepatitis C virus genome. Lancet 1995; 346: 425426.
  • 43
    McHutchison JG, Sedghi-Vaziri A, Russell J, Schmid P, Conrad A. Is there an optimal time to measure quantitative HCV RNA to predict outcome following interferon treatment for chronic HCV infection? [Abstract]. Hepatology 1996; 24: 356A.